News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Biotech/Pharma - Investor
Amgen (AMGN), Sandoz, Inc. Biosimilar War Could Provide Playbook, Says Analyst 10/30/2014
Synergy Pharmaceuticals Announces Full Exercise Of Over-Allotment Option 10/30/2014
Neptune Technologies & Bioressources Inc. Receives TSX Approval For Normal Course Issuer Bid 10/30/2014
Chimerix, Inc. (CMRX) Announces Commencement Of Public Offering Of Common Stock 10/30/2014
Ambit Biosciences Announces Expiration Of Hart-Scott-Rodino Waiting Period 10/30/2014
Roche Holdings, Inc. Announces Debt Tender Offer 10/30/2014
Ebola Epidemic Unlikely But Not Impossible, Says Immunovaccine Inc. CEO 10/29/2014
Under Immense Pressure, Amgen (AMGN) Outlines Strategy 10/29/2014
Cowen: Amgen (AMGN)’s Plans Are “Music To Our Ears" 10/29/2014
Ampio Pharmaceuticals, Inc. (AMPE) Could Have A Blockbuster Fourth Quarter, Says Citi 10/29/2014
Corbus Pharmaceuticals, Inc. Commences Trading On OTCQB Under Ticker Symbol CRBP 10/29/2014
Synergy Pharmaceuticals Announces Private Offering Of Convertible Senior Notes 10/29/2014
NeuroVive Pharmaceutical AB: Annual General Meeting 2015 And Information About Members Appointed To The Nomination Committee 10/29/2014
Synergy Pharmaceuticals Announces Pricing Of Private Offering Of $175 Million Of 7.50% Convertible Senior Notes 10/29/2014
Regulus Therapeutics, Inc. (RGLS) Announces Pricing Of Public Offering Of Common Stock 10/29/2014
AtheroNova Inc. (AHRO.OB) Prices Public Offering Of Common Stock And Warrants 10/29/2014
Novo Nordisk A/S (NVO) - Share Repurchase Programme 10/29/2014
Vanda Pharmaceuticals, Inc. (VNDA) Proposes Public Offering Of Common Stock 10/29/2014
Foamix Pharmaceuticals, Ltd. (FOMX) To Host Key Opinion Leader Meeting And Webcast On November 4th In New York City 10/29/2014
Merck & Co. (MRK) Execs “Downplaying” Gilead Sciences, Inc. (GILD)'s Harvoni Competitor, Says Analyst 10/28/2014
Amgen (AMGN) Tells Analysts It Will Improve Margins 15% By Axing 4,000 Jobs 10/28/2014
Sanofi (SAN.PA) Delivers Business EPS Growth of 10.3% At CER 10/28/2014
Nordic Nanovector – Registered Share Capital Increase 10/28/2014
Celator Pharmaceuticals, Inc. Announces Completion Of Its Public Offering And The Exercise In Full Of Option To Purchase Additional Units Of Common Stock And Warrants To Purchase Common Stock 10/28/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Entry Into $20 Million "At-The-Market" Equity Distribution Agreement With Canaccord Genuity Inc. 10/28/2014
Regulus Therapeutics, Inc. (RGLS) Announces Commencement Of Public Offering Of Common Stock 10/28/2014
Repros Therapeutics Inc. (RPRX) To Webcast Investor And Analyst Day On October 31st 10/28/2014
Vitae Pharmaceuticals, Inc. (VTAE) Announces Exercise Of Underwriters' Option To Purchase Additional Shares Of Initial Public Offering 10/28/2014
Pfizer (PFE)'s $11 Billion Buyback Dims Prospects Of AstraZeneca PLC (AZN) Bid 10/27/2014
Citi: Sarepta Therapeutics (SRPT) Will See Competition, Concern Over FDA Delay 10/27/2014
Tug-Of-War Over Revlimid Patent Continues Between Celgene (CELG), Natco Pharma Limited 10/24/2014
Ocera Therapeutics, Inc. (OCRX)’s New HE Drug Could Pull Stock Up Out Of Rut: Cowen 10/24/2014
Strong Earnings Could Mean Buying Spree For Alexion Pharmaceuticals Inc. (ALXN), Says Analyst 10/24/2014
Nordic Nanovector: Issuance Of Shares To HealthCap VI L.P 10/24/2014
AptarGroup Declares Quarterly Dividend 10/24/2014
CEL-SCI (CVM) Announces Closing Of Public Offering For Gross Proceeds Of $6 Million 10/24/2014
Zafgen (ZFGN) To Ring The Nasdaq Stock Market Closing Bell 10/24/2014
PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change And Launches New Corporate Website 10/24/2014
Amgen (AMGN) To Webcast 2014 Business Review Meeting On October 28 10/24/2014
Celgene (CELG) Beats The Street Again On Earnings And Analysts Couldn’t Be Happier 10/23/2014
TetraPhase PharmaceuticalsAnnounces Closing Of Public Offering Of Common Stock 10/23/2014
Notice Of Extraordinary General Meeting Of Medivir AB (MVRBF) (Publ) 10/23/2014
Celator Pharmaceuticals, Inc. Announces Pricing Of A $12.9 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock 10/23/2014
Innocoll AG Proposes Changes To Supervisory Board And Stock Option Plan 10/23/2014
Hold Your Horses On Splicing Amgen (AMGN), Say Citi Analysts 10/22/2014
Esperion Therapeutics, Inc. (ESPR) Announces Closing Of Follow-On Public Offering And Exercise In Full Of Underwriters’ Option To Purchase Additional Shares Of Common Stock 10/22/2014
Amgen (AMGN) Statement Regarding Third Point Investment 10/22/2014
Flexion Therapeutics (FLXN) To Ring The Nasdaq Stock Market Opening Bel 10/22/2014
Clovis Oncology (CLVS) To Announce Third Quarter 2014 Financial Results And Host Webcast Conference Call On November 6 10/22/2014
Bioren, Inc. Announces Additional Orders For $1.7 Million 10/22/2014
Kythera Biopharmaceuticals (KYTH) Grants Stock Options Under Inducement Program 10/22/2014
Celgene (CELG)’s New Crohn’s Disease Drug Impressing Analysts 10/21/2014
ISI Group: AbbVie (ABBV)’s Dividend, Repurchasing Attempt Could Mean More Debt 10/21/2014
Tianyin Pharmaceutical Co, Inc. Received Notices Of Non-Compliance From NYSE MKT 10/21/2014
CEL-SCI (CVM) Announces Proposed Public Offering Of Common Stock And Warrants 10/21/2014
Nine-Month Figures For 2014: Sartorius Grows In Order Intake, Sales Revenue And Earnings 10/21/2014
Fluidigm Corporation To Announce Q3 2014 Financial Results And Host Conference Call For Investors 10/21/2014
Metabolix, Inc. To Conduct Webcast Of Its Third Quarter Fiscal Year 2014 Earnings Call 10/21/2014
HEALTHSOUTH Declares Dividend On Common Stock And Dividend On 6.5% Series A Convertible Perpetual Preferred Stock 10/21/2014
Techne Corp. (TECH) Release: Bio-Techne To Host Conference Call On October 28, 2014 To Announce First Quarter Financial Results 10/21/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Amendment To Common Share Purchase Agreement With Lincoln Park Capital Fund, LLC 10/21/2014
AbbVie (ABBV) Announces New $5 Billion Stock Repurchase Program And Increases Dividend 10/21/2014
Aptose Biosciences Announces Approval For Listing On The NASDAQ Capital Market Shares To Begin Trading Under The Symbol APTO 10/21/2014
Aurinia (ISA.TO) To Host Lupus Opinion Leader Meeting And Webcast On October 23 In New York City 10/21/2014
Ablynx (ABLYF) Announces Warrant Exercise 10/21/2014
SWK Holdings Corporation Establishes Record Date For Rights Offering 10/21/2014
Full Blown Ebola Epidemic Unlikely In U.S., Says Specialist 10/20/2014
Current Climate The Best For Biotech IPOs In Decades, Says VC 10/20/2014
Exclusive: Fewer Deals, Capital In Biotech In Q3 But Sector Remains Popular, Says VC 10/20/2014
DBV Technologies Announces Proposed Global Offering 10/20/2014
Acasti Pharma Announces Grant Of Stock Options 10/20/2014
Cowen and Company: Best Buys, Favorable Biotech Outlook Remain 10/17/2014
AbbVie (ABBV) Still A Buy Despite Shire Fallout, Says Analyst 10/17/2014
TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007 10/17/2014
VG Life Sciences, Inc. (VGLS) Announces Upgrading To OTCQB Marketplace 10/17/2014
Celator Pharmaceuticals, Inc. Announces Public Offering Of Common Stock And Warrants To Purchase Common Stock 10/17/2014
Sunshine Biopharma, Inc. Retains Renmark Financial Communications To Provide Investor Relations 10/17/2014
TetraPhase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock 10/17/2014
Agios Pharmaceuticals (AGIO) Smart Buy Ahead Of Cancer Data: Citi 10/16/2014
Roche (RHHBY) Lucentis, Regeneron (REGN) Eylea Continue To Battle It Out In Eye Market 10/16/2014
Medivir AB (MVRBF): Optimization Of Capital Structure 10/16/2014
Roche (RHHBY) Delivers Solid Sales Growth For The First Nine Months Of 2014 10/16/2014
Anatara Lifesciences Successfully Lists On The ASX 10/16/2014
TetraPhase Pharmaceuticals Announces Proposed Public Offering Of Common Stock 10/16/2014
Nasdaq Welcomes Atara Biotherapeutics (ATRA) To The Nasdaq Stock Market 10/16/2014
Esperion Therapeutics, Inc. (ESPR) Prices Public Offering Of Common Stock 10/16/2014
Ligand Pharmaceuticals Inc. (LGND) To Host Analyst Day On November 18th In New York City 10/16/2014
Portage Completes Non-Brokered Private Placement For A Total Proceeds Of US$2,000,000 10/16/2014
Relypsa, Inc. (RLYP) Announces New Employment Inducement Grants 10/16/2014
Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants 10/16/2014
Selecta Biosciences, Inc. Announces More Than $20 Million In Equity Funding 10/15/2014
Walking Dead: Biotech "Zombie" Companies And Why They Are Failing 10/15/2014
Nasdaq Welcomes Forward Pharma (FWP) To The Nasdaq Stock Market 10/15/2014
Esperion Therapeutics, Inc. (ESPR) Announces Proposed Public Offering Of Common Stock 10/15/2014
Merck & Co. (MRK) Announces Pricing Of Tender Offers For Eight Series Of Notes 10/15/2014
UBS: Gilead Sciences, Inc. (GILD) Remains Solid Buy Despite Irish Tax Changes, Price War 10/15/2014
Announcement Regarding Submission Of Tender Offer For Shares In Ambit Biosciences 10/15/2014
Orexo AB (ORXOF) Appoints Nomination Committee And Publishes Financial Calendar 2014/2015 10/15/2014
Tianyin Pharmaceutical Co, Inc. Provides Update On Filing Of Form 10-K For Fiscal Year Ended June 30, 2014 10/15/2014
Sensient Technologies Corporation Announces Conference Call 10/15/2014
ContraVir Pharmaceuticals Closes $9.0 Million Financing To Advance Lead Shingles Candidate 10/15/2014
Transcept Pharmaceuticals, Inc. (TSPT) Declares Special Dividend Of $12.79 Million And Additional Contingent Future Amounts In Connection With Its Merger With Paratek Pharmaceuticals, Inc. 10/15/2014
Tauriga Sciences Inc. (TAUG) Completely Free Of Convertible Debt 10/15/2014
Neptune Technologies & Bioressources Inc. Announces Normal Course Issuer Bid 10/15/2014
VG Life Sciences, Inc. (VGLS) Announces SEC Form 10 Review Complete 10/15/2014
ChrysCapital In Talks With Private Equity Firms To Sell 11% In Mankind Pharma 10/15/2014
New Irish Tax Rules Won’t Faze Biotech: Analyst 10/14/2014
Immunodiagnostic Systems Holdings plc Trading Update 10/14/2014
Oxford BioMedica PLC (OXB.L) Director's Share Purchase 10/14/2014
Easton Pharmaceuticals (OP: EAPH) Secures Financing Commitment Towards Closing Of Its Option On Canadian Medical Marijuana Facility And Business 10/14/2014
Preliminary Q3 2014 Report: CytoSorbents, Inc. Achieves Its First Quarter of Approximately $1M in CytoSorb® Sales and Provides Up-listing Update 10/14/2014
Nextech Venture Invest Announces First Closing Of Oncology Fund IV 10/14/2014
Sunshine Biopharma, Inc. Retains Renmark Financial Communications To Provide Investor Relations 10/14/2014
Spinal Atrophy Drug From Isis Pharmaceuticals, Inc. (ISIS) Showing Promise, Says UBS 10/13/2014
Analysts: Harvoni News Nothing But Upside For Gilead Sciences, Inc. (GILD) 10/13/2014
Cytori Therapeutics, Inc. (CYTX) Announces Closing Of Financing 10/13/2014
Bristol-Myers Squibb Company (BMY) To Hold Investor Teleconference To Discuss CMSTO Highlights 10/13/2014
Chimerix, Inc. (CMRX) To Webcast R&D Update On October 15th 10/13/2014
Kythera Biopharmaceuticals (KYTH) Grants Stock Options Under Inducement Program 10/13/2014
Repligen Corporation (RGEN) To Host Investor & Analyst Event On October 16 10/13/2014
PRAC Decision On Leukemia Drug Good News For Ariad Pharmaceuticals, Inc. (ARIA), Says Analyst 10/10/2014
BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech 10/10/2014
MabVax Therapeutics, Inc. Announces Stock Ticker Symbol Change To MBVX 10/10/2014
Anacor Pharmaceuticals, Inc. (ANAC) Announces Pricing Of Offering Of $75 Million Of 2.00% Convertible Senior Notes Due 2021 10/10/2014
DiaGenic ASA: Ex Right To Receive Subscription Rights In The Rights Issue Today, 10 October 2014 10/10/2014
PTC Therapeutics, Inc. (PTCT) Announces Pricing Of Public Offering Of Common Stock 10/10/2014
Synthetic Biologics, Inc. (SYN) To Raise $20.7 Million In Registered Direct Offering 10/10/2014
Gilead Sciences, Inc. (GILD) Will Have Higher Revenues, EPS On Liver Drug Strength: Citi 10/9/2014
CPhI Panel Warns ‘Commitment Dilution’ Hindering Drug Development And Price Pressure Compromising Safety 10/9/2014
Anacor Pharmaceuticals, Inc. (ANAC) Announces Proposed Offering Of $70 Million Of Convertible Senior Notes Due 2021 10/9/2014
AVANIR Pharmaceuticals (AVNR) To Host Investor Briefing On October 15, 2014 10/9/2014
Arrowhead Research Corporation (ARWR) Issues Open Letter To Shareholders 10/9/2014
PTC Therapeutics, Inc. (PTCT) Announces Proposed Public Offering Of Common Stock 10/9/2014
Skyepharma PLC (SKYEF) – Interim Management Statement 10/9/2014
Cross-Over Investing All The Rage, Say VCs On Panel 10/9/2014
Aegerion Pharmaceuticals, Inc. (AEGR) Grants Stock Options Under Inducement Program 10/9/2014
Traders’ Infatuation With Ebola Drugs Causing “Rollercoaster” Market, Says Tekmira (TKMR) CEO 10/8/2014
Sand Hill Angels Continues To Invest In Mobile And The Cloud Participating In Perkville's $2.4 Million Dollar Series A 10/8/2014
Cytori Therapeutics, Inc. (CYTX) Raises $13.5 Million In Registered Direct Offering 10/8/2014
Radius (RDUS) Announces Closing Of Public Offering Of Common Stock And Partial Exercise Of Underwriters' Option To Purchase Additional Shares 10/7/2014
Medivir AB (MVRBF) Capital Markets Meeting on 16 October 2014 10/7/2014
Exostar Obtains $5 Million Investment For Their Growing Healthcare Business 10/7/2014
Oncologix Tech, Inc.  (OTCBB: OCLG) Continues Debt Reduction Strategy; Strengthens Company's Stock Position And Shareholder Value 10/7/2014
Avidity NanoMedicines Expands Investor Syndicate 10/7/2014
BioDelivery Sciences International (BDSI) To Provide BUNAVAIL Launch Update 10/7/2014
Cellular Biomedicine Group (CBMG) Calls For General Annual Stockholder Meeting On November 07, 2014 10/7/2014
Asterias Biotherapeutics To List Its Series A Common Stock On NYSE MKT 10/7/2014
Therapix Biosciences ADRs Begin Trading On The OTCQB® 10/7/2014
Retrophin (RTRX) Booted CEO For Multiple Stock Violations: Report 10/6/2014
Merck & Co. (MRK) Announces Proposed Public Debt Offering 10/6/2014
Merck & Co. (MRK) Announces Tender Offers For Eight Series Of Notes 10/6/2014
Vitrolife (VITR.ST): Invitation To Capital Markets Day On November 6 10/6/2014
iBio, Inc. (IBIO) Reports On Filing Of 2014 Annual Report 10/6/2014
Medtech Startup Embo Medical Secures €3 Million Investment 10/6/2014
Cord Blood America, Inc. Announces Divestiture Of Biocordcell Argentina, S.A. 10/6/2014
LabStyle Innovations Implements 1-For-5 Reverse Stock Split 10/6/2014
Pivotal Therapeutics Inc. Announces Payment Of Interest On Outstanding Convertible Notes 10/6/2014
Agios Pharmaceuticals (AGIO) To Webcast R&D Day On October 15, 2014 10/6/2014
Biotech Boom On Third Coast Proves Everything's Bigger In Texas 10/3/2014
Retrophin (RTRX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 10/3/2014
Salix Pharmaceuticals, Ltd. (SLXP) To Ring The Nasdaq Stock Market Closing Bell 10/3/2014
Venture Capital Pours Into Biotech For Biggest Quarter Since 2012: Report 10/3/2014
Piper Jaffray: Companies Should Start Stockpiling Now For Ebola 10/3/2014
Antibe Therapeutics Inc. Reports on Results of AGM Voting 10/3/2014
Opexa Therapeutics (OPXA) Announces Analyst And Investor Event 10/3/2014
Sevion Therapeutics Announces New Ticker Symbol “SVON” 10/3/2014
Mylan Inc. (MYL) Increases Third Quarter And Full Year 2014 Adjusted Diluted EPS Guidance Range 10/3/2014
Vital Therapies, Inc. (VTI) (VTL) Announces Pricing Of Follow-On Offering 10/3/2014
Portola Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock 10/3/2014
Perrigo Company (PRGO) Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 10/2/2014
Aptose Biosciences Announces Reverse Stock Split 10/2/2014
ISS Urges Allergan Inc. (AGN) To Give Investors Vote, Questions Credibility 10/2/2014
Chimerix, Inc. (CMRX)’s Brincidofovir An Ebola Standout For Traders, Says Analyst 10/2/2014
Veracyte, Inc. (VCYT) To Host Investor Day On October 9, 2014 10/2/2014
Radius (RDUS) Announces Pricing Of Public Offering 10/2/2014
Lightlake Therapeutics Inc. (LLTP) Announces Closing Of Investments In Two Products 10/2/2014
Pfenex Inc. (PFNX) Added To Both Russell Microcap® Index And Russell Global Indexes 10/2/2014
Momenta Pharmaceuticals, Inc. (MNTA) To Host 2014 R&D Day 10/2/2014
Resverlogix Corporation (RVX.TO) Corporate Update Conference Call & Webcast Announcement 10/2/2014
Portola Pharmaceuticals, Inc. Announces Proposed Offering Of Common Stock 10/2/2014
JSS Medical Research Announces Equity Investment By Capital Croissance PME (CCPME) 10/2/2014
Radius (RDUS) Announces Proposed Public Offering 10/2/2014
Abstracts For Merck & Co. (MRK), Gilead Sciences, Inc. (GILD) And AbbVie (ABBV) Look Promising, Says ISI 10/1/2014
Ardelyx Inc. (ARDX) Looks Good After Tenanpanor Results: Citi Analysts 10/1/2014
Conversion Right Triggered for Laboratory Corporation of America Holdings (LabCorp) (LH)’s Zero Coupon Convertible Subordinated Notes Due 2021 10/1/2014
H&Q Life Sciences Investors Pays Stock Distribution 10/1/2014
BrainStorm Cell Therapeutics Inc. Completes Uplisting To The NASDAQ Capital Market 10/1/2014
Aerie Pharmaceuticals, Inc. (AERI) Announces Closing Of $125 Million Convertible Notes Financing 10/1/2014
Perrigo Company (PRGO) Announces Extension Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 10/1/2014
Assembly Biosciences Announces $15.75 Million Registered Direct Offering 10/1/2014
Otonomy, Inc. (OTIC) Added To Russell 2000® Index 10/1/2014
Vital Therapies, Inc. (VTI) (VTL) Announces Launch Of Proposed Follow-On Offering 10/1/2014
If Allergan Inc. (AGN) Survives Valeant (VRX), AbbVie (ABBV), Shire or Actavis (ACT)/Forest May Be Suitors 9/30/2014
Pfizer (PFE) Will Wait Out Midterm Elections For Favorable Inversion Laws: Analyst 9/30/2014
Allergy Therapeutics plc Release: Amendment Of 2012 Loan Note Term 9/30/2014
TNI BioTech's CEO Issues Letter To Shareholders Discussing Cytocom Dividend 9/30/2014
Catabasis Pharmaceuticals, Inc. Management To Present At October Investor Conferences 9/30/2014
Portage Announces Conversion Of Its Debt Into Equity 9/30/2014
Alimera Sciences (ALIM) Provides Details On FDA Approval Of Iluvien® As The First Long-Term Treatment For Diabetic Macular Edema 9/29/2014
Analysts Say Valeant Pharmaceuticals International (VRX)/Allergan Inc. (AGN) Deal Could Lead To Buying Spree 9/29/2014